Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Laboratories (CLB) Gains from Investment Securities (2022 - 2026)

Core Laboratories filings provide 5 years of Gains from Investment Securities readings, the most recent being $730000.0 for Q1 2026.

  • On a quarterly basis, Gains from Investment Securities rose 183.72% to $730000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $920000.0, a 494.85% increase, with the full-year FY2025 number at $894109.0, up 7.62% from a year prior.
  • Gains from Investment Securities hit $730000.0 in Q1 2026 for Core Laboratories, up from $170000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $1.3 million in Q4 2024 to a low of -$872000.0 in Q1 2025.
  • Median Gains from Investment Securities over the past 5 years was $170000.0 (2025), compared with a mean of $38800.0.
  • Biggest five-year swings in Gains from Investment Securities: skyrocketed 1303.77% in 2024 and later plummeted 328.87% in 2025.
  • Core Laboratories' Gains from Investment Securities stood at $436000.0 in 2022, then tumbled by 124.31% to -$106000.0 in 2023, then skyrocketed by 1303.77% to $1.3 million in 2024, then plummeted by 86.68% to $170000.0 in 2025, then soared by 329.41% to $730000.0 in 2026.
  • The last three reported values for Gains from Investment Securities were $730000.0 (Q1 2026), $170000.0 (Q4 2025), and -$286000.0 (Q3 2025) per Business Quant data.